Efpeglenatide vs Flaxseed

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Efpeglenatide vs Flaxseed: Flaxseed has the stronger overall evidence (6.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Flaxseed Edges Ahead

Flaxseed wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Efpeglenatide0 wins

Flaxseed3 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Efp4.3

Efpeglenatide

Too few graded studiesLimited safety

Flx6.5

Flaxseed

Too few graded studiesHigh safety

Evidence

Evidence Score

4.3/10

Studies: 21

Meta-analyses: 8

Level: Emerging

Evidence Score

Best6.5/10

Studies: 163

Meta-analyses: 26

Level: Moderate

Research findings

Verdict

Too few graded studies

Top outcomes

Glycemic controlToo few graded studies20
Cardiovascular & renal outcomesToo few graded studies9
Weight & body compositionToo few graded studies7

Verdict

Too few graded studies

Top outcomes

Women's healthToo few graded studies27
Glucose & metabolicToo few graded studies21
Heart & blood pressureToo few graded studies13

Shared outcomes (2)

Outcomes where both Efpeglenatide and Flaxseed have evidence — compare verdict strength side-by-side.

Glucose & metabolicToo few graded studies20Too few graded studies21
Heart & blood pressureToo few graded studies9Too few graded studies13

Dosage & timing

Recommended Dosage:

SupStack does not provide a self-directed dosing protocol for Efpeglenatide. A dose used in a clinical trial does not establish a safe consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration.

Warnings

INVESTIGATIONAL DRUG — efpeglenatide is NOT FDA-approved or marketed anywhere and is NOT a dietary supplement. Despite strong cardiorenal trial data it was not carried to approval; it is not a prescribable treatment.
The cardiorenal results are genuinely strong (AMPLITUDE-O: ~27% MACE reduction and ~32% kidney-outcome reduction vs placebo), but these are CARDIOVASCULAR and RENAL outcomes — NOT a demonstrated lifespan/longevity or healthspan outcome.
GREY-MARKET RISK: never obtain efpeglenatide from research-chemical or grey-market vendors — it is an unapproved investigational drug with no clinical oversight, no identity/purity/sterility guarantee, and no dosing standard.
GLP-1-class gastrointestinal effects (nausea, vomiting, diarrhea, constipation, bloating) are COMMON and dose-dependent — requiring slow titration; some treatment discontinuation occurred.
Expected GLP-1-class thyroid C-cell (medullary thyroid carcinoma) warning applies pending long-term human data; pancreatitis and gallbladder events are class cautions.
Long-term safety and durability beyond the trial windows are not established for efpeglenatide specifically.

Best Time:

Once a week

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (investigational only)

Recommended Dosage:

30g (about 3-4 tablespoons) of ground/milled flaxseed daily

Warnings

Use ground/milled flaxseed — whole seeds largely pass undigested
Take with adequate water to avoid GI discomfort from the fiber
Flaxseed oil and isolated lignan extracts underperform whole flaxseed in trials

Best Time:

With meals

Take with food

Best Form:

Ground / milled flaxseed

Safety

Limited safety

Drug Interactions:

Other GLP-1 / incretin drugs (severe)
Oral medications (delayed gastric emptying) (moderate)
Insulin / insulin secretagogues (sulfonylureas) (moderate)

Side Effects:

Nausea / vomitingDiarrhea / constipation / bloatingTreatment discontinuation due to adverse events

Contraindications:

Not a dietary supplement and not an approved/marketed drug — investigational; do not self-source grey-market vials
Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell precaution, not a product-label contraindication: this investigational drug has no label, and not every approved GLP-1 product carries the US thyroid boxed warning)

High safetyBest

Drug Interactions:

Antihypertensives (mild)
Anticoagulants / antiplatelets (mild)
Oral medications generally (mild)

and 1 more not shown

Side Effects:

Bloating, gas, flatulenceLoose stools / increased bowel movements

Contraindications:

Bowel obstruction or strictures (high fiber)
Known flax allergy

Shared goals

Support heart healthEfpeglenatide

Efpeglenatide66/100

Flaxseed62/100

Manage blood sugarEfpeglenatide

Efpeglenatide64/100

Flaxseed42/100

What you'll notice

❤️ Reduced major cardiovascular events (MACE)positive

Over ~1.8 years (trial follow-up)

🫘 Reduced kidney-outcome eventspositive

Over ~1.8 years

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Weight losspositive

Months (titrated)

❤️ Blood pressure reductionpositive

8-12 weeks

🩸 Modest LDL reductionpositive

8-12 weeks

📉 Small glycemic improvementpositive

12 weeks

💨 GI effects from fibernegative

First 1-2 weeks

Key studies

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=4076

Pivotal randomized, placebo-controlled cardiovascular-outcomes trial (n=4,076) at 344 sites in 28 countries, in type 2 diabetes with either a history of cardiovascular disease or current kidney disease (eGFR 25.0-59.9) plus at least one other cardiovascular risk factor; weekly subcutaneous efpeglenatide 4 or 6 mg vs placebo, median follow-up 1.81 years

Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.

Diabetes Obes Metab (2024) · Observational · n=3983

Prespecified epidemiological analysis of AMPLITUDE-O data (n=3,983 with baseline eGFR/UACR) relating kidney-disease indices to MACE and the composite kidney outcome and testing whether efpeglenatide's effect varies with them

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.

Diabetes Care (2022) · Rct

Phase-3 double-blind, placebo-controlled monotherapy RCT in type 2 diabetes inadequately controlled with diet and exercise; once-weekly efpeglenatide 2/4/6 mg vs placebo for up to 56 weeks

All Efpeglenatide studies

Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial.

Clin Nutr (2016) · Meta analysis · n=1302

15 trials (19 treatment arms), 1302 participants

Potent antihypertensive action of dietary flaxseed in hypertensive patients.

Hypertension (2013) · Rct · n=110

Double-blind, placebo-controlled RCT, 110 patients, 6 months

Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials.

Nutr Rev (2018) · Meta analysis

25 RCTs (30 treatment arms)

All Flaxseed studies

Frequently asked questions

Is Efpeglenatide better than Flaxseed?

Flaxseed has a higher evidence score (6.5/10 vs 4.3/10) and wins in 3 of 3 categories.

Is Efpeglenatide or Flaxseed better for support heart health?

For support heart health, Efpeglenatide has a higher relevance score (66 vs 62).

Can I take Efpeglenatide and Flaxseed together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Flaxseed vs Iron Flaxseed vs Whey Protein Flaxseed vs Tirzepatide Flaxseed vs Liraglutide

Still deciding between Efpeglenatide and Flaxseed?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Efpeglenatide details Flaxseed details

Warnings

INVESTIGATIONAL DRUG — efpeglenatide is NOT FDA-approved or marketed anywhere and is NOT a dietary supplement. Despite strong cardiorenal trial data it was not carried to approval; it is not a prescribable treatment.

The cardiorenal results are genuinely strong (AMPLITUDE-O: ~27% MACE reduction and ~32% kidney-outcome reduction vs placebo), but these are CARDIOVASCULAR and RENAL outcomes — NOT a demonstrated lifespan/longevity or healthspan outcome.

GREY-MARKET RISK: never obtain efpeglenatide from research-chemical or grey-market vendors — it is an unapproved investigational drug with no clinical oversight, no identity/purity/sterility guarantee, and no dosing standard.

GLP-1-class gastrointestinal effects (nausea, vomiting, diarrhea, constipation, bloating) are COMMON and dose-dependent — requiring slow titration; some treatment discontinuation occurred.

Expected GLP-1-class thyroid C-cell (medullary thyroid carcinoma) warning applies pending long-term human data; pancreatitis and gallbladder events are class cautions.

Long-term safety and durability beyond the trial windows are not established for efpeglenatide specifically.

Frequently asked questions

Is Efpeglenatide better than Flaxseed?

Flaxseed has a higher evidence score (6.5/10 vs 4.3/10) and wins in 3 of 3 categories.

Is Efpeglenatide or Flaxseed better for support heart health?

For support heart health, Efpeglenatide has a higher relevance score (66 vs 62).

Can I take Efpeglenatide and Flaxseed together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.